Fig. 3
From: Severe restless legs syndrome in a family with Alport syndrome
(a) Average actigraphic motor activity before (black area) and after (white area) drug management. (b) One-week actigraphic recording during treatment with immediate release pramipexole 0.75 mg/day, showing severe insomnia and high levels of motor activity during daytime. (c) One-week actigraphic recording after therapeutic shifting to pramipexole 0.75 mg plus clonazepam 0.5 mg, at bedtime, showing a significant improvement of both night sleep and a motor activity during daytime